AXSM
Axsome Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Axsome Therapeutics has 9 disclosed suppliers and 3 disclosed customers in SEC filings.
Last report2 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
+3.83%
vs ±9.0% implied · ×0.43
shaded = implied · ▲▼ = realized
SentenceIn November 2025, Avenue announced it had entered into an agreement for Baergic to be acquired by Axsome, including the global rights to BAER-101 (also known as AZD7325), a novel oral GABAA α2,3 subtype-selective receptor positive allosteric modulator ("PAM").
SentenceIn May 2022, the Company acquired the U.S. rights to SUNOSI ® (solriamfetol) from Jazz Pharmaceuticals plc ("Jazz"), and in November 2022, the Company acquired worldwide ex-U.S. rights (excluding certain Asian markets) from Jazz (collectively, the "Acquisition").
SentenceIn January 2020, the Company entered into an exclusive license agreement with Pfizer Inc. ("Pfizer") for Pfizer's clinical and non-clinical data, and intellectual property for reboxetine, the active pharmaceutical ingredient in AXS-12 which the Company is developing for the treatment of narcolepsy.
SentenceAt the initial closing, we assumed all of the commitments of Jazz to SK and Aerial.
AXSM 10-Kaccession 0001193125-26-064267
SentenceIn 2014, Jazz acquired from Aerial worldwide rights to SUNOSI excluding those Asian markets stated previously.
AXSM 10-Kaccession 0001193125-26-064267
SentenceUnder three exclusive license agreements with Antecip, an entity owned by our Chief Executive Officer and Chairman of the Board, Herriot Tabuteau, M.D., we are obligated to make specified royalty payments ranging from 1.5% to 4.5%, subject to up to a 50% reduction depending on required payments to third parties, on net sales of our products containing the licensed technology of AXS-02, AXS-05, and AXS-04.
AXSM 10-Kaccession 0001193125-26-064267
SentenceIn December 2025, we acquired the global rights to deuterium-stabilized S-bupropion from DeuteRx.
AXSM 10-Kaccession 0001193125-26-064267
SentenceSK is the originator of SUNOSI and retains rights in 12 Asian markets, including China, Korea, and Japan.
AXSM 10-Kaccession 0001193125-26-064267
SentenceIn February 2023, the Company announced a licensing transaction with Atnahs Pharma UK Limited ("Pharmanovia") to market SUNOSI in Europe and certain countries in the Middle East / North Africa.
AXSM 10-Kaccession 0001193125-26-064267
Sentence
in the fourth quarter of 2024, we recorded a milestone revenue of $0.5 million related to an achievement of a regulatory milestone in China for SUNOSI from SK.
AXSM 10-Kaccession 0001193125-26-064267
SentenceThe Company sells AUVELITY, SUNOSI, and SYMBRAVO in the United States to wholesale distributors with whom the Company has entered into formal agreements (collectively, the "Distributors").
AXSM 10-Kaccession 0001193125-26-064267
Axsome Therapeutics, Inc.
144.63
Linked news
Expected move
Inputs8Q avg ±3.9%·×2.66·rich
straddle ±12.7%
spot 144.43exp Nov 20ATM strike 145ATM straddle 21.65IV 78%